Verkauf durch Sack Fachmedien

Smolen / Lipsky

Targeted Therapies in Rheumatology

Medium: Buch
ISBN: 978-1-84184-157-1
Verlag: CRC Press
Erscheinungstermin: 19.12.2002
Lieferfrist: bis zu 10 Tage
This textbook serves as a comprehensive reference on the latest science underlying the development of biological therapies, as well as their use in animal and human studies of rheumatological disease. Part A covers targets of emerging therapies - targeting/manipulating cells, targeting cell surface receptors, targeting cytokines, inflammatory mediators and transcription factors, and targeting plasma molecules. Part B then examines the use and implementation of these new therapies in the clinic, covering their use in treating specific rheumatological conditions. Part C discusses issues relating to study design and regulatory issues in the US and Europe.

Produkteigenschaften


  • Artikelnummer: 9781841841571
  • Medium: Buch
  • ISBN: 978-1-84184-157-1
  • Verlag: CRC Press
  • Erscheinungstermin: 19.12.2002
  • Sprache(n): Englisch
  • Auflage: 1. Auflage 2002
  • Produktform: Gebunden
  • Gewicht: 1791 g
  • Seiten: 768
  • Format (B x H x T): 189 x 246 x 37 mm
  • Ausgabetyp: Kein, Unbekannt

Autoren/Hrsg.

Autoren

Smolen, Josef S.

Lipsky, Peter

Part A. Targets. Section I: Targeting/Manipulating Cells. T-cells. B-cells. Macrophages. Dendritic cells. Neutrophils. Fibroblasts. Mast Cells. Section II: Targeting Cell Surface Receptors. Complement Receptors. Fc-Receptors. CD-28. Fas. Section III: Targeting Cytokines. TNF-alpha. IL-1. IL-6. IL-18. IL-12. IL-15. Th1/Th2 balance a) Experimental models of rheumatological diseases b) Human disease. OPG. Chemokines. The balance between pro- and anti- inflammatory cytokines. Section IV. Targeting Inflammatory Mediators and Transcription Factors. iNOS. COX/PG synthases. Matrix molecules. NFkB. Jak/STATs. MMPs. Angiogenesis. Section V: Targeting. Immunoglobulins. Complement. Apheresis. Part B. Studies in Human and Experimental Rheumatic Diseases. Ethical Issues. Rheumatoid Arthritis. Biologics in Early Arthritis. Juvenile Arthritis. Psoriatic arthritis/psoriasis. Spondylarthritis. Systemic Lupus Erythematosus. Vasculitis. Myositis. Part C. Study Design. Randomized Controlled Trials. Long-Term Observational Studies. Long-Term Monitoring of Experimental (Novel) Therapies. Community-Based Studies. Regulatory Issues - FDA Index. Section II: Targeting Cell Surface Receptors. Section III: Targeting Cytokines. Section IV: Targeting Inflammatory mediators and Transcription Factors.